Details of the Drug

General Information of Drug (ID: DMXIMQT)

Drug Name
APX-3330
Synonyms AR-03; E-3330; APE1 inhibitors (cancer/retinopathy), ApeX Therapeutics; APX-3330 analogs (cancer/retinopathy),ApeX Therapeutics; E-3330 analogs (cancer/retinopathy), ApeX Therapeutics
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
Ocular cancer 2D00-2D07 Discontinued in Phase 2 [2]
Structure
3D MOL 2D MOL
Cross-matching ID
PubChem CID
6439397
TTD ID
D0U8XW
Drug-Molecule Activity Atlas (DMA)NEW Click to Jump to the Detailed DMA Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
AP endonuclease 1 (APEX1) TTHGL48 APEX1_HUMAN Inhibitor [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035303)
3 Inhibition of APE1/Ref-1 redox activity with APX3330 blocks retinal angiogenesis in vitro and in vivo. Vision Res. 2011 Jan;51(1):93-100.